Discovery Labs (DSCO +17.9%) could be acquired, speculates Roth Capital. Following the approval...

|By:, SA News Editor

Discovery Labs (DSCO +17.9%) could be acquired, speculates Roth Capital. Following the approval of its synthetic surfactant, Surfaxin, by the FDA, Roth says the company could sell itself, or obtain a partner. It raises its target on the shares to $10 from $6 while maintaining its Buy rating.